Open AccessEffect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
Author(s) -
Ivy Song,
Julie Borland,
Shuguang Chen,
Parul Patel,
Toshihiro Wajima,
Amanda Peppercorn,
Stephen C. Piscitelli
Publication year - 2012
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.05739-11
Subject(s) - dolutegravir , pharmacokinetics , integrase inhibitor , crossover study , integrase , medicine , pharmacology , food and drug administration , food science , human immunodeficiency virus (hiv) , virology , chemistry , antiretroviral therapy , viral load , alternative medicine , pathology , placebo
Healthy subjects received dolutegravir at 50 mg in a single-dose crossover study while they were in the fasted state or with low-, moderate-, or high-fat meals. Food increased dolutegravir exposure and reduced the rate of absorption. The area under the concentration-time curve from 0 h to infinity (AUC0–∞ ) increased by 33%, 41%, and 66% when administered with low-, moderate-, or high-fat meals, respectively, compared with fasting. This increase in dolutegravir exposure is not anticipated to impact clinical safety, and therefore dolutegravir can be taken with or without food and without regard to fat content.